Cargando…
Preserved SARS-CoV-2 neutralizing IgG activity of in-house manufactured COVID-19 convalescent plasma
PURPOSE: In the current study, we aimed to evaluate the neutralizing IgG activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as well as the coagulation factors of convalescent plasmas which we manufactured in-house without a fast-freezing technique. METHODS: We collected pl...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797217/ https://www.ncbi.nlm.nih.gov/pubmed/36610860 http://dx.doi.org/10.1016/j.transci.2022.103638 |
_version_ | 1784860648006483968 |
---|---|
author | Inada, Makoto Togano, Tomiteru Terada, Mari Shiratori, Katsuyuki Tsuzuki, Shinya Takamatsu, Yuki Saito, Sho Hangaishi, Akira Morioka, Shinichiro Kutsuna, Satoshi Maeda, Kenji Mitsuya, Hiroaki Ohmagari, Norio |
author_facet | Inada, Makoto Togano, Tomiteru Terada, Mari Shiratori, Katsuyuki Tsuzuki, Shinya Takamatsu, Yuki Saito, Sho Hangaishi, Akira Morioka, Shinichiro Kutsuna, Satoshi Maeda, Kenji Mitsuya, Hiroaki Ohmagari, Norio |
author_sort | Inada, Makoto |
collection | PubMed |
description | PURPOSE: In the current study, we aimed to evaluate the neutralizing IgG activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as well as the coagulation factors of convalescent plasmas which we manufactured in-house without a fast-freezing technique. METHODS: We collected plasmas from eligible participants who had confirmed certain titers of neutralizing antibodies. The plasmas were frozen and stored in the ordinary biofreezer without a fast-freezing function. The purified-IgG neutralizing activity of 20 samples from 19 participants and the coagulation factors of 49 samples from 40 participants were evaluated before and after freezing. RESULTS: Purified-IgG maintained its neutralizing activities, with the median 50 % inhibitory concentration (IC50) of 10.11 mg/ml (IQR 6.53–18.19) before freezing and 8.90 m g/ml (IQR 6.92–28.27) after thawing (p = 0.956). On the contrary, fibrinogen and factor Ⅷ decreased significantly after freezing and thawing in our environment. No significant temperature deviation was observed during the storage period. CONCLUSION: Neutralizing IgG activity, which largely contributes to the antiviral activity of convalescent plasma, did not change through our in-house manufacturing, without fastfreezing and storage conditions for more than 200 days. Ordinary freezers without the fast-freezing function are suitable enough to manufacture and store convalescent plasmas. Hospitals or facilities without specified resources could easily collect and store convalescent plasmas in case of upcoming emerging or re-emerging infectious diseases on-demand with appropriate neutralizing antibody levels measurements. |
format | Online Article Text |
id | pubmed-9797217 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97972172022-12-29 Preserved SARS-CoV-2 neutralizing IgG activity of in-house manufactured COVID-19 convalescent plasma Inada, Makoto Togano, Tomiteru Terada, Mari Shiratori, Katsuyuki Tsuzuki, Shinya Takamatsu, Yuki Saito, Sho Hangaishi, Akira Morioka, Shinichiro Kutsuna, Satoshi Maeda, Kenji Mitsuya, Hiroaki Ohmagari, Norio Transfus Apher Sci Article PURPOSE: In the current study, we aimed to evaluate the neutralizing IgG activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as well as the coagulation factors of convalescent plasmas which we manufactured in-house without a fast-freezing technique. METHODS: We collected plasmas from eligible participants who had confirmed certain titers of neutralizing antibodies. The plasmas were frozen and stored in the ordinary biofreezer without a fast-freezing function. The purified-IgG neutralizing activity of 20 samples from 19 participants and the coagulation factors of 49 samples from 40 participants were evaluated before and after freezing. RESULTS: Purified-IgG maintained its neutralizing activities, with the median 50 % inhibitory concentration (IC50) of 10.11 mg/ml (IQR 6.53–18.19) before freezing and 8.90 m g/ml (IQR 6.92–28.27) after thawing (p = 0.956). On the contrary, fibrinogen and factor Ⅷ decreased significantly after freezing and thawing in our environment. No significant temperature deviation was observed during the storage period. CONCLUSION: Neutralizing IgG activity, which largely contributes to the antiviral activity of convalescent plasma, did not change through our in-house manufacturing, without fastfreezing and storage conditions for more than 200 days. Ordinary freezers without the fast-freezing function are suitable enough to manufacture and store convalescent plasmas. Hospitals or facilities without specified resources could easily collect and store convalescent plasmas in case of upcoming emerging or re-emerging infectious diseases on-demand with appropriate neutralizing antibody levels measurements. Elsevier Ltd. 2023-06 2022-12-29 /pmc/articles/PMC9797217/ /pubmed/36610860 http://dx.doi.org/10.1016/j.transci.2022.103638 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Inada, Makoto Togano, Tomiteru Terada, Mari Shiratori, Katsuyuki Tsuzuki, Shinya Takamatsu, Yuki Saito, Sho Hangaishi, Akira Morioka, Shinichiro Kutsuna, Satoshi Maeda, Kenji Mitsuya, Hiroaki Ohmagari, Norio Preserved SARS-CoV-2 neutralizing IgG activity of in-house manufactured COVID-19 convalescent plasma |
title | Preserved SARS-CoV-2 neutralizing IgG activity of in-house manufactured COVID-19 convalescent plasma |
title_full | Preserved SARS-CoV-2 neutralizing IgG activity of in-house manufactured COVID-19 convalescent plasma |
title_fullStr | Preserved SARS-CoV-2 neutralizing IgG activity of in-house manufactured COVID-19 convalescent plasma |
title_full_unstemmed | Preserved SARS-CoV-2 neutralizing IgG activity of in-house manufactured COVID-19 convalescent plasma |
title_short | Preserved SARS-CoV-2 neutralizing IgG activity of in-house manufactured COVID-19 convalescent plasma |
title_sort | preserved sars-cov-2 neutralizing igg activity of in-house manufactured covid-19 convalescent plasma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797217/ https://www.ncbi.nlm.nih.gov/pubmed/36610860 http://dx.doi.org/10.1016/j.transci.2022.103638 |
work_keys_str_mv | AT inadamakoto preservedsarscov2neutralizingiggactivityofinhousemanufacturedcovid19convalescentplasma AT toganotomiteru preservedsarscov2neutralizingiggactivityofinhousemanufacturedcovid19convalescentplasma AT teradamari preservedsarscov2neutralizingiggactivityofinhousemanufacturedcovid19convalescentplasma AT shiratorikatsuyuki preservedsarscov2neutralizingiggactivityofinhousemanufacturedcovid19convalescentplasma AT tsuzukishinya preservedsarscov2neutralizingiggactivityofinhousemanufacturedcovid19convalescentplasma AT takamatsuyuki preservedsarscov2neutralizingiggactivityofinhousemanufacturedcovid19convalescentplasma AT saitosho preservedsarscov2neutralizingiggactivityofinhousemanufacturedcovid19convalescentplasma AT hangaishiakira preservedsarscov2neutralizingiggactivityofinhousemanufacturedcovid19convalescentplasma AT moriokashinichiro preservedsarscov2neutralizingiggactivityofinhousemanufacturedcovid19convalescentplasma AT kutsunasatoshi preservedsarscov2neutralizingiggactivityofinhousemanufacturedcovid19convalescentplasma AT maedakenji preservedsarscov2neutralizingiggactivityofinhousemanufacturedcovid19convalescentplasma AT mitsuyahiroaki preservedsarscov2neutralizingiggactivityofinhousemanufacturedcovid19convalescentplasma AT ohmagarinorio preservedsarscov2neutralizingiggactivityofinhousemanufacturedcovid19convalescentplasma |